>
GURUFOCUS.COM > STOCK LIST > Healthcare > Biotechnology > VistaGen Therapeutics Inc (NAS:VTGN) > Definitions > Total Inventories
Switch to:

VistaGen Therapeutics Total Inventories

: $0.00 Mil (As of Mar. 2022)
View and export this data going back to 2011. Start your Free Trial

VistaGen Therapeutics's total inventories for the quarter that ended in Mar. 2022 was $0.00 Mil. VistaGen Therapeutics's average total inventories from the quarter that ended in Dec. 2021 to the quarter that ended in Mar. 2022 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. VistaGen Therapeutics's Net-Net Working Capital per share for the quarter that ended in Mar. 2022 was $0.28.

Inventory can be measured by days sales of inventory (DSI). VistaGen Therapeutics's days sales of inventory (DSI) for the three months ended in Mar. 2022 was 0.00.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. VistaGen Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2022 was 0.00.


VistaGen Therapeutics Total Inventories Historical Data

The historical data trend for VistaGen Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VistaGen Therapeutics Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22
Total Inventories
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

VistaGen Therapeutics Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Total Inventories Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

VistaGen Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


VistaGen Therapeutics  (NAS:VTGN) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

VistaGen Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2022 is

Net-Net Working Capital Per Share (Q: Mar. 2022 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(68.135+0.75 * 0+0.5 * 0-9.928
-0-0)/206.541
=0.28

2. Inventory can be measured by Days Sales of Inventory (DSI).

VistaGen Therapeutics's Days Sales of Inventory for the three months ended in Mar. 2022 is

Days Sales of Inventory (DSI)
=Total Inventories (Q: Mar. 2022 )/Revenue (Q: Mar. 2022 )*Days in Period
=0/0.039*365 / 4
=0.00

3. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

VistaGen Therapeutics's Days Inventory for the three months ended in Mar. 2022 is calculated as:

Days Inventory=Total Inventories (Q: Mar. 2022 )/Cost of Goods Sold (Q: Mar. 2022 )*Days in Period
=0/0*365 / 4
=

4. Inventory Turnover measures how fast the company turns over its inventory within a year.

VistaGen Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2022 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2022 ) / Total Inventories (Q: Mar. 2022 )
=0 / 0
=N/A

5. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

VistaGen Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2022 is calculated as

Inventory-to-Revenue=Total Inventories (Q: Mar. 2022 ) / Revenue (Q: Mar. 2022 )
=0 / 0.039
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


VistaGen Therapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of VistaGen Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


VistaGen Therapeutics Business Description

VistaGen Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
N/A
Address
343 Allerton Avenue, South San Francisco, CA, USA, 94080
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
Executives
Saxe Jon S director FIRST HORIZON PHARMACEUTICAL CORP 660 HEMBREE PKWY STE 106 ROSWELL GA 30076
Dotson Jerrold Duane officer: VP, CFO AND SECRETARY 5 CENTERPOINTE DRIVE SUITE 400 LAKE OSWEGO OR 97035
Singh Shawn director, officer: CHIEF EXECUTIVE OFFICER C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Snodgrass H. Ralph director, officer: PRES./CHIEF SCIENTIFIC OFFICER 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080
Smith Mark Alan officer: CHIEF MEDICAL OFFICER 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Mcpartland Mark A. officer: VP CORPORATE DEVELOPMENT C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Gin Jerry B director 343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080
Underdown Brian J. director C/O LUMIRA CAPITAL INVESTMENT MANAGEMENT 141 ADELAIDE ST. WEST, SUITE 770 TORONTO ONTARIO CANADA M5H 3L5 A6 00000
Cunningham Ann Michelle director 255 N CALDWELL CIRCLE DOWNINGTOWN PA 19335
Rice A. Franklin officer: VP CORPORATE DEVELOPMENT 384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080
Bonfiglio Gregory A. director 384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080
Platinum Long Term Growth Vii, Llc 10 percent owner 152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019
Cato Holding Co 10 percent owner 4364 SOUTH ALSTON AVENUE DURHAM NC 27713
Cato Allen Easley 10 percent owner 4364 SOUTH ALSTON AVENUE DURHAM NC 27713
Jones Stephanie director, 10 percent owner, officer: PRESIDENT 13834 W. HOYT ROAD RATHDRUM ID 83858

VistaGen Therapeutics Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)